TY - JOUR
T1 - Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study
AU - Tanaka, Yoshiya
AU - Yamazaki, Kiyotaka
AU - Nakajima, Ryo
AU - Komatsu, Shuichi
AU - Igarashi, Ataru
AU - Tango, Toshiro
AU - Takeuchi, Tsutomu
PY - 2018/1/2
Y1 - 2018/1/2
N2 - Objectives: The objective of this study is to evaluate the economic impact of adalimumab (ADA) on Japanese rheumatoid arthritis (RA) patients. Methods: ANOUVEAU was a 48-week multicenter, prospective, observational, single-cohort study. Work-related outcomes including absenteeism, presenteeism, overall work impairment (OWI), and activity impairment (AI) were evaluated using the RA-related work productivity and activity impairment (WPAI/RA). The amount of productivity loss was estimated via multiplication of absenteeism, presenteeism and OWI by the national average occupational wage for paid worker (PW) and part time worker (PTW), and via multiplication of AI by the estimated wage for domestic work for home maker (HM). Results: In this analysis, 1196 patients were included. At week 48, measures of productivity loss due to absenteeism, presenteeism, OWI, and AI were significantly improved by administrating ADA to RA patients in all employment types (PW, PTW, and HM), compared to baseline (p <.01). Productivity loss of Japanese society by RA disease was estimated to be $9.80 billion. The annual decrease in productivity loss through ADA administration to Japanese RA patients was estimated to be $3.76 billion. Conclusions: The socioeconomic burden of RA is high, but ADA treatment may reduce productivity loss related to RA.
AB - Objectives: The objective of this study is to evaluate the economic impact of adalimumab (ADA) on Japanese rheumatoid arthritis (RA) patients. Methods: ANOUVEAU was a 48-week multicenter, prospective, observational, single-cohort study. Work-related outcomes including absenteeism, presenteeism, overall work impairment (OWI), and activity impairment (AI) were evaluated using the RA-related work productivity and activity impairment (WPAI/RA). The amount of productivity loss was estimated via multiplication of absenteeism, presenteeism and OWI by the national average occupational wage for paid worker (PW) and part time worker (PTW), and via multiplication of AI by the estimated wage for domestic work for home maker (HM). Results: In this analysis, 1196 patients were included. At week 48, measures of productivity loss due to absenteeism, presenteeism, OWI, and AI were significantly improved by administrating ADA to RA patients in all employment types (PW, PTW, and HM), compared to baseline (p <.01). Productivity loss of Japanese society by RA disease was estimated to be $9.80 billion. The annual decrease in productivity loss through ADA administration to Japanese RA patients was estimated to be $3.76 billion. Conclusions: The socioeconomic burden of RA is high, but ADA treatment may reduce productivity loss related to RA.
KW - Disease burden
KW - Japan
KW - activity impairment
KW - biologics
KW - work productivity
UR - http://www.scopus.com/inward/record.url?scp=85023778120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023778120&partnerID=8YFLogxK
U2 - 10.1080/14397595.2017.1341459
DO - 10.1080/14397595.2017.1341459
M3 - Article
C2 - 28704126
AN - SCOPUS:85023778120
VL - 28
SP - 39
EP - 47
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 1
ER -